DrugPatentWatch Database Preview
Maraviroc - Generic Drug Details
What are the generic drug sources for maraviroc and what is the scope of maraviroc freedom to operate?
Maraviroc
is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in two NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.There are two drug master file entries for maraviroc. Three suppliers are listed for this compound. There are two tentative approvals for this compound.
Summary for maraviroc
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| Drug Master File Entries: | 2 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 66 |
| Clinical Trials: | 125 |
| Patent Applications: | 3,464 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | maraviroc at DailyMed |
Pharmacology for maraviroc
| Drug Class | CCR5 Co-receptor Antagonist |
| Mechanism of Action | Chemokine Co-receptor 5 Antagonists |
Synonyms for maraviroc
| (non-labelled)Maraviroc-d6 |
| [3H]maraviroc |
| [3H]UK 427,857 |
| [3H]UK-427,857 |
| 348M651 |
| 376348-65-1 |
| 4,?4-?DIFLUORO-?N-?[(1S)-?3-?[(3-?EXO)-?3-?[3-?METHYL-?5-?(1-?METHYLETHYL)-?4H-?1,?2,?4-?TRIAZOL-?4-?YL]-?8-?AZABICYCLO[3.2.1]OCT-?8-?YL]-?1-?PHENYLPROPYL]-?CYCLOHEXANECARBOXAMIDE |
| 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[(1S,5S)-3-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-phenyl-propyl}-amide |
| 4,4-difluoro-N-((1S)-3-((1R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide |
| 4,4-difluoro-N-((1S)-3-((1R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide |
| 4,4-difluoro-N-((1S)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide |
| 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide |
| 4,4-difluoro-N-((S)-3-((1S,3R,5R)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide |
| 4,4-difluoro-N-((S)-3-((1S,3S,5R)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide |
| 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide |
| 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide |
| 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide |
| 4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide |
| 4,4-DIFLUORO-N-[(1S)-3-[(1S,5R)-3-(3-METHYL-5-PROPAN-2-YL-1,2,4-TRIAZO L-4-YL)-8-AZABICYCLO[3.2.1]OCT-8-YL]-1-PHENYL-PROPYL]CYCLOHEXANE-1-CAR BOXAMIDE |
| 4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide |
| 4,4-Difluoro-N-[(1s)-3-{(3-Exo)-3-[3-Methyl-5-(Propan-2-Yl)-4h-1,2,4-Triazol-4-Yl]-8-Azabicyclo[3.2.1]oct-8-Yl}-1-Phenylpropyl]cyclohexanecarboxamide |
| 4,4-difluoro-N-{(1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide |
| 674782-29-7 |
| ABP000248 |
| AC-558 |
| AC1MHEFQ |
| AKOS025402143 |
| AKOS032946723 |
| API0003256 |
| BC297754 |
| BDBM50334986 |
| BRD-A23284911-001-02-4 |
| C29H41F2N5O |
| Celsentri |
| Celsentri (TN) |
| Celsentri(TM) |
| CHEBI:63608 |
| CHEMBL1201187 |
| CHEMBL256907 |
| CHEMBL584744 |
| CS-0366 |
| CTK5C6225 |
| CYCLOHEXANECARBOXAMIDE 4 4-DIFLUORO-N-[(1S)-3-[(3-EXO)-3-[3-METHYL-5-(1-METHYLETHYL)-4H-1 2 4-TRIAZOL-4-YL]-8-AZABICYCLO[3.2.1]OCT-8-YL]-1-PHENYLPROPYL]- |
| Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-((3-exo)-3-(3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)- |
| D0NR6S |
| D0T8DO |
| DB04835 |
| EX-A200 |
| exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide |
| FT-0654501 |
| GSNHKUDZZFZSJB-QYOOZWMWSA-N |
| GTPL803 |
| GTPL806 |
| HE070818 |
| HE116184 |
| HY-13004 |
| Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide |
| J-521678 |
| LS-182818 |
| Maraviroc [USAN] |
| Maraviroc, >=98% (HPLC) |
| Maraviroc(Selzentry)/UK-427857 |
| Maraviroc|376348-65-1|Selzentry|Celsentri |
| maravirocum |
| maravirok |
| marawirok |
| MCULE-2702173987 |
| MD6P741W8A |
| MFCD13188530 |
| MLS006011960 |
| MolPort-020-005-896 |
| MolPort-044-728-878 |
| MRV |
| MVC |
| NCGC00183109-01 |
| NCGC00183109-02 |
| PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide |
| PRO 140 & Maraviroc |
| PubChem18277 |
| Rel-Maraviroc |
| RL03435 |
| RT-013662 |
| SC-47577 |
| SCHEMBL2177194 |
| SCHEMBL4576508 |
| SCHEMBL51991 |
| Selzentry |
| Selzentry (TN) |
| Selzentry(TM) |
| SMR004703532 |
| SR-01000942244 |
| SR-01000942244-1 |
| UK 427857 |
| UK-427,857 |
| UK-427,857 maraviroc (MVC) |
| UK-427857 |
| UNII-MD6P741W8A |
| X5004 |
| Z1618161028 |
| ZINC100003902 |
| ZINC101160855 |
| ZINC3817234 |
US Patents and Regulatory Information for maraviroc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-002 | Aug 6, 2007 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-002 | Aug 6, 2007 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-003 | Nov 4, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Viiv Hlthcare | SELZENTRY | maraviroc | SOLUTION;ORAL | 208984-001 | Nov 4, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-002 | Aug 6, 2007 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for maraviroc
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1039942 | ➤ Sign Up |
| China | 1279040 | ➤ Sign Up |
| Japan | 2002533461 | ➤ Sign Up |
| Gulf Cooperation Council | 0000117 | ➤ Sign Up |
| Turkey | 200200938 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for maraviroc
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 1284974/01 | Switzerland | ➤ Sign Up | FORMER OWNER: PFIZER INC., US |
| 0338 | Netherlands | ➤ Sign Up | |
| 4 | Finland | ➤ Sign Up | |
| C0007 | France | ➤ Sign Up | PRODUCT NAME: MARAVIROC; REGISTRATION NO/DATE: EU/1/07/418/001 20070918 |
| 2008 | Austria | ➤ Sign Up | PRODUCT NAME: MARAVIROC, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: